• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Emerg Microbes Infect . Influenza A hemagglutinin virus-like particles confer protection against influenza B virus infection

tetano

Editor, Senior Moderator
Emerg Microbes Infect


. 2025 Apr 15:2494702.
doi: 10.1080/22221751.2025.2494702. Online ahead of print. Influenza A hemagglutinin virus-like particles confer protection against influenza B virus infection

Jie Mao[SUP] 1 [/SUP], Ki Back Chu[SUP] 2 3 [/SUP], Gi-Deok Eom[SUP] 1 [/SUP], Keon-Woong Yoon[SUP] 1 [/SUP], Su In Heo[SUP] 1 [/SUP], Hae-Ji Kang[SUP] 4 [/SUP], Sung Soo Kim[SUP] 5 [/SUP], Fu-Shi Quan[SUP] 5 6 [/SUP]



Affiliations
Abstract

Influenza A hemagglutinin (HA), neuraminidase, and/or M2e-containing virus-like particles (VLPs) induce immune responses that contribute to protection against multiple influenza A virus subtypes. In this study, we investigated the protective efficacy of influenza A/H1H3 VLPs against influenza B virus infections (B/Colorado/06/2017 and B/Malaysia/2506/2004, Victoria lineage) in mice. A/H1H3 VLP immunization elicited protection against lethal challenge infections with both B/Colorado and B/Malaysia, significantly reducing lung viral loads and ensuring 100% survival of immunized mice. Sera from A/H1H3VLP-immunized mice recognized inactivated B/Colorado and B/Malaysia virus antigens and enhanced Fc receptor-mediated antibody-dependent cellular cytotoxicity (ADCC) responses. Notably, immune sera reacted with HA, HA1, and HA2 antigens from both B/Colorado and B/Malaysia viruses. A/H1H3VLP immunization also induced lung IgG and IgA antibody responses against HA, HA1, and HA2 of both B viruses, as well as antibody-secreting cell responses (ASC), germinal center B (GC B) responses, and CD4[SUP]+[/SUP] T cell responses. Additionally, A/H1H3VLP immunization significantly suppressed pro-inflammatory cytokines responses (IFN-γ, IL-6). These results suggest that A/H1H3 VLP hold promise as a candidate for a universal influenza vaccine capable of providing cross-protection against influenza B virus infection.

Keywords: antibody responses; cross-protection; universal influenza vaccine; viral burden regulation; virus-like particles.

 
Back
Top Bottom